Author: Anna Forrester|| Date Published: March 10, 2017
TYSONS CORNER, VA, March 10, 2017 ” A subsidiary of CSRA (NYSE: CSRA) has secured orphan drug status from the Food and Drug Administration on a plague vaccine it is developing as a potential pre-exposure prophlaxis treatment against Yersinia pestis infection, ExecutiveBiz reported Thursday.
The company said Wednesday the designation enables DynPort Vaccine Company to receive incentives in its work to develop the recombinant rF1V vaccine as part of the Defense Department‘s medical countermeasure efforts against bioterrorism.
About Executive Mosaic: Founded in 2002, Executive Mosaic is a leadership organization and media company. Executive Mosaic offers highly coveted executive events, breaking business news on the Government Contracting industry, and delivers robust and reliable content through seven influential websites and four consequential E-newswires. Headquarters are located in Tysons Corner, VA. www.executivemosaic.com
Contact: David Smith (703) 226-7002 david.smith@executivemosaic.com
Potomac Officers Club, the Capital region’s foremost government contracting events and networking organization, is thrilled to introduce its summer series for…
Heather Gerczak, chief administrative officer at Integral Federal, has been named chair of Executive Mosaic’s 4×24 Contracts Group. The 4×24 Executive Leadership…
Iridium Communications (Nasdaq: IRDM) presented its Q1 2024 financial results, in which total revenue reacched $203.9 million, although slightly lower…
TYSONS CORNER, VA, March 10, 2017 ” A subsidiary of CSRA (NYSE: CSRA) has secured orphan drug status from the Food and Drug Administration on a plague vaccine it is developing as a potential pre-exposure prophlaxis treatment against Yersinia pestis infection, ExecutiveBiz reported Thursday.
